Dr.Many compounds exhibit synergistic activity in the investigated cancer cell lines
where Dasatinib and the WEE1 kinase inhibitor MK-1775 seemed to be promising
candidates for further investigations.During his
work at the Molecular Medicine Institute, Dr. Hmeidat explored novel molecularly
targeted combination therapies for squamous carcinoma of the head and neck
cancer.